Mani Foroohar
Stock Analyst at Leerink Partners
(1.51)
# 2,305
Out of 4,412 analysts
146
Total ratings
42.22%
Success rate
-14.44%
Average return
Main Sectors:
Top Industries:
25 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVAC CureVac | Downgrades: Market Perform | $12 → $4 | $2.33 | +71.67% | 2 | Apr 25, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $44 → $43 | $24.46 | +75.80% | 10 | Mar 18, 2024 | |
| RGNX REGENXBIO | Upgrades: Outperform | n/a | $16.19 | - | 7 | Mar 6, 2024 | |
| ENGN enGene Holdings | Initiates: Outperform | $31 | $15.50 | +100.00% | 1 | Feb 20, 2024 | |
| ALVR AlloVir | Downgrades: Market Perform | $1 | $0.80 | +25.45% | 9 | Dec 22, 2023 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $12 | $4.66 | +157.51% | 4 | Dec 19, 2023 | |
| TNYA Tenaya Therapeutics | Initiates: Outperform | $7 | $4.31 | +62.41% | 1 | Nov 30, 2023 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $19 | $12.50 | +52.00% | 1 | Nov 28, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Downgrades: Market Perform | $40 | $22.12 | +80.83% | 10 | May 12, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $25 → $27 | $24.88 | +8.52% | 11 | Apr 13, 2023 | |
| FDMT 4D Molecular Therapeutics | Maintains: Market Perform | $14 → $13 | $23.25 | -44.09% | 7 | Apr 13, 2023 | |
| MRNA Moderna | Downgrades: Underperform | $111 → $93 | $107.97 | -13.86% | 16 | Feb 24, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $34 → $27 | $41.59 | -35.08% | 11 | Feb 23, 2023 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $9 → $8 | $8.12 | -1.48% | 6 | Jan 23, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $50 → $49 | $21.98 | +122.93% | 9 | Jan 23, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $86 → $84 | $20.76 | +304.62% | 4 | Jan 23, 2023 | |
| EDIT Editas Medicine | Maintains: Market Perform | $6 → $7 | $5.32 | +31.58% | 4 | Jan 23, 2023 | |
| BLUE bluebird bio | Maintains: Market Perform | $9 → $8 | $0.92 | +766.93% | 7 | Jan 23, 2023 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $81 → $77 | $21.38 | +260.15% | 2 | Jan 23, 2023 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Market Perform | $144 → $143 | $143.31 | -0.22% | 8 | Jan 23, 2023 | |
| ABEO Abeona Therapeutics | Maintains: Market Perform | $5 → $6 | $3.26 | +84.05% | 4 | Nov 14, 2022 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $75 → $76 | $53.91 | +40.98% | 1 | Nov 7, 2022 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $30 → $34 | $3.71 | +816.44% | 4 | May 12, 2022 | |
| ADVM Adverum Biotechnologies | Maintains: Market Perform | $50 → $20 | $9.19 | +117.63% | 6 | Jul 23, 2021 | |
| AVRO AVROBIO | Maintains: Market Perform | n/a | $1.21 | - | 1 | May 3, 2021 |
CureVac
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $2.33
Upside: +71.67%
Mirum Pharmaceuticals
Mar 18, 2024
Maintains: Outperform
Price Target: $44 → $43
Current: $24.46
Upside: +75.80%
REGENXBIO
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $16.19
Upside: -
enGene Holdings
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $15.50
Upside: +100.00%
AlloVir
Dec 22, 2023
Downgrades: Market Perform
Price Target: $1
Current: $0.80
Upside: +25.45%
Wave Life Sciences
Dec 19, 2023
Upgrades: Outperform
Price Target: $12
Current: $4.66
Upside: +157.51%
Tenaya Therapeutics
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $4.31
Upside: +62.41%
Lexeo Therapeutics
Nov 28, 2023
Initiates: Outperform
Price Target: $19
Current: $12.50
Upside: +52.00%
Arrowhead Pharmaceuticals
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $22.12
Upside: +80.83%
BridgeBio Pharma
Apr 13, 2023
Maintains: Outperform
Price Target: $25 → $27
Current: $24.88
Upside: +8.52%
4D Molecular Therapeutics
Apr 13, 2023
Maintains: Market Perform
Price Target: $14 → $13
Current: $23.25
Upside: -44.09%
Moderna
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $107.97
Upside: -13.86%
Ionis Pharmaceuticals
Feb 23, 2023
Maintains: Market Perform
Price Target: $34 → $27
Current: $41.59
Upside: -35.08%
Recursion Pharmaceuticals
Jan 23, 2023
Maintains: Market Perform
Price Target: $9 → $8
Current: $8.12
Upside: -1.48%
Rocket Pharmaceuticals
Jan 23, 2023
Maintains: Outperform
Price Target: $50 → $49
Current: $21.98
Upside: +122.93%
Intellia Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $20.76
Upside: +304.62%
Editas Medicine
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $5.32
Upside: +31.58%
bluebird bio
Jan 23, 2023
Maintains: Market Perform
Price Target: $9 → $8
Current: $0.92
Upside: +766.93%
Beam Therapeutics
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $21.38
Upside: +260.15%
Alnylam Pharmaceuticals
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $143.31
Upside: -0.22%
Abeona Therapeutics
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $3.26
Upside: +84.05%
CRISPR Therapeutics AG
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $53.91
Upside: +40.98%
Caribou Biosciences
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.71
Upside: +816.44%
Adverum Biotechnologies
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $9.19
Upside: +117.63%
AVROBIO
May 3, 2021
Maintains: Market Perform
Price Target: n/a
Current: $1.21
Upside: -